z-logo
open-access-imgOpen Access
Formulation and clinical translation of [177Lu]Lu-trastuzumab for radioimmunotheranostics of metastatic breast cancer
Author(s) -
Mohini Guleria,
Rohit Sharma,
Jeyachitra Amirdhanayagam,
Haladhar Dev Sarma,
Venkatesh Rangarajan,
Ashutosh Dash,
Tapas Das
Publication year - 2021
Publication title -
rsc medicinal chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.754
H-Index - 55
ISSN - 2632-8682
DOI - 10.1039/d0md00319k
Subject(s) - trastuzumab , medicine , metastatic breast cancer , oncology , breast cancer , cancer
Trastuzumab (Herceptin®) is an approved immunotherapeutic agent used for the treatment of metastatic breast cancer over-expressing HER2 antigen receptors. The aim of the present work is to standardize the formulation protocol of [ 177 Lu]Lu-trastuzumab addressing various reaction parameters, evaluating the efficacy of the radiolabeled product by in vitro investigations, scaling-up the preparation for administration in patients and performing preliminary clinical studies in patients suffering from metastatic breast cancer. Trastuzumab was conjugated with a suitable bi-functional chelating agent namely, p -NCS-benzyl-DOTA. On average 6.15 ± 0.92 p -NCS-benzyl-DOTA molecules were observed to be attached to each trastuzumab moiety. [ 177 Lu]Lu-trastuzumab could be prepared with >95% radiochemical purity (% RCP) employing the optimized radiolabeling procedure. In vitro studies revealed the affinity of [ 177 Lu]Lu-trastuzumab towards HER2 +ve cancer cell lines as well as against HER2 protein ( K d = 13.61 nM and 11.36 nM, respectively). The value for percentage immunoreactive fraction (% IRF) for [ 177 Lu]Lu-trastuzumab was observed to be 76.92 ± 2.80. Bio-distribution studies in Swiss mice revealed non-specific uptake in the blood, liver, lungs and heart followed by gradual clearance of activity predominantly through the hepatobiliary route. Preliminary clinical studies carried out in 8 cancer patients with immunohistochemically proven HER2 positive metastatic breast cancer revealed preferential localization of [ 177 Lu]Lu-trastuzumab in breast cancer lesions, which was in concordance with [ 18 F]FDG-PET scans recorded earlier in the same patient indicating the potential of the agent towards radioimmunotheranostic applications.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here